Neonc Technologies Holdings Inc (NTHI)

$12.00 -0.11 (-0.91%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 9,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and s...

Industry: Biotechnology
Sector: Healthcare
Phone: 310-663-7831
Address:
23975 Park Sorrento, Suite 205, Calabasas, United States
NeOnc_Technologies
NeOnc_Technologies Nov. 26 at 1:22 PM
$NTHI Amir Heshmatpour on recent completion of enrollment in pivotal NEO100 Phase 2a trial for IDH-1 mutant recurrent high-grade glioma and expectation of interim data readout in Q2 2026: “Having now completed full enrollment, we can comprehensively assess NEO100’s impact across a complete patient population. The strength of the data observed to date reinforces our confidence that our proprietary intranasal delivery platform — uniquely designed to bypass the blood-brain barrier represents a breakthrough approach for treating aggressive brain tumors. We believe these data will not only strengthen our clinical position but also strategically advance NeOnc toward becoming a global leader in CNS oncology innovation, with a first-mover advantage and a defensible moat protecting our extensive intellectual property portfolio.”
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 26 at 5:29 AM
$NTHI NeOnc Technologies Holdings Inc. (OTC:NTHI) delivered a major breakthrough in CNS oncology with NEO100 showing a 21 percent response rate versus less than 8 percent historically, 44 percent six-month PFS, and 33 percent eighteen-month survival in recurrent high-grade gliomas. As NTHI advances toward a May 2026 top-line readout and a $50 million Middle East partnership, investor interest is surging. https://biotechhealthx.com/biotech-news/neonc-technologies-nthi-stuns-wall-street-with-breakthrough-21-response-rate-in-brain-cancer-trial/
0 · Reply
topstockalerts
topstockalerts Nov. 25 at 8:03 PM
Top Gainers PT2 $BNED $WSHP $NTHI $QNTM $KZIA
0 · Reply
topstockalerts
topstockalerts Nov. 25 at 7:51 PM
$NTHI It wants to move higher..
0 · Reply
50shadesoftrades
50shadesoftrades Nov. 25 at 7:33 PM
$CETY $CSTE $PAVS $DKI $NTHI Intraday gainers https://go.trade-ideas.com/SH16c
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 25 at 8:22 AM
$NTHI NeOnc Technologies delivered a strong Q3 marked by strategic expansion in the Middle East, meaningful non-dilutive funding, enhanced market visibility, and strengthened leadership across both corporate and scientific fronts. Middle East Expansion: NuroMENA appointed His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signed an MSA with M42’s IROS, completed ADGM incorporation, and advanced a proposed $50M partnership with Quazar Investment. Non-Dilutive Funding: Awarded $2.5M in NIH STTR grants to advance NEO212 for gliomas and leukemia. Tech Expansion: Executed agreement to acquire advanced AI + 3D bioprinting IP. Media Visibility: Featured on Fox Business, Bloomberg TV, Yahoo Finance’s Trader Talk, a 12-part New to The Street campaign, and a live interview with Kenny Polcari. Index Inclusion: Added to the Russell Microcap® Index. IP Strength: Global patents protecting core CNS oncology assets. https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-holdings-reports-third-quarter-2025-results
0 · Reply
AlertsAndNews
AlertsAndNews Nov. 25 at 3:31 AM
$NTHI insider action here Neonc Technologies Holdings, Inc.: Amir F. Heshmatpour (Director, President, 10%+) Buys 30,000 Shares @ Avg Price $6.16 – Form 4
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 20 at 10:05 AM
$NTHI NeOnc Technologies Q3 2025 Financial Results & Operational Highlights NeOnc Technologies delivered a defining Q3 2025 Financial Results and Operational Highlights, advancing both clinical and strategic milestones: - G&A expenses: $903K vs. $244K in Q3 2024, reflecting expanded marketing, travel, and Middle East partnership-related costs. - R&D expenses: $715K vs. $957K in Q3 2024, supporting NEO100 trial site management, patient recruitment, NEO212 preparation, and initiation of NEO100-3. - Net loss: $8.6M ($0.45 per share) vs. $2.2M ($0.12 per share) in Q3 2024, primarily due to increased G&A and stock-based compensation. Amir Heshmatpour: “Q3 2025 positions NeOnc at the forefront of innovation in CNS oncology. We delivered encouraging Phase 2a NEO100 data, signaling a potential paradigm shift for recurrent high-grade gliomas. We also achieved FDA clearance for NEO212 Phase 2 trials, strengthening the depth and momentum of our pipeline.”
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 18 at 10:04 AM
$NTHI Last week was an incredible week for NeOnc. We announced 3 milestones that together underscore our momentum and position us for meaningful value creation in the CNS oncology space: Updated NEO100 clinical results: In 24 patients with recurrent IDH1‑mutant high-grade gliomas, NEO100 showed a 21% radiographic response rate, 44% progression-free survival at 6 months, and 33% of patients alive at 18+ months. No significant chronic toxicity was observed. Full enrollment of pivotal Phase 2a trial: Our trial for recurrent IDH1-mutant high-grade gliomas is now fully enrolled. Interim data is expected in Q2 2026. Q3 2025 results & operational updates: $50M strategic partnership via NuroMENA, $2.5M in STTR grants to advance NEO212, and listing in the Russell Microcap® Index. Net loss of $8.6M reflects strategic investment in pipeline growth. This is only the beginning for NeOnc. We aim to transform CNS oncology and bring new hope to patients.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 17 at 11:35 PM
$NTHI NeOnc Technologies: Exciting Upcoming Catalysts • We’re entering a pivotal period for value creation with three major near-term milestones: • Q4 2025: Completion of NEO212 Phase I final cohort dosing. • May 2026: Top-line data readout from NEO100-01 pivotal Phase 2a trial. Near-term: Closing and funding of the $50M Quazar Investment, supporting our CNS oncology pipeline and strategic growth. These catalysts mark critical steps in advancing our mission to deliver innovative therapies for patients with challenging CNS cancers. #CNSOncology #ClinicalTrials #Biotech #Investors #NEO100 #NEO212
0 · Reply
Latest News on NTHI
NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

Nov 13, 2025, 9:00 AM EST - 14 days ago

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

Nov 7, 2025, 9:00 AM EST - 20 days ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

NeOnc Technologies: From Survival Mode To Expansion Mode

Oct 9, 2025, 2:25 PM EDT - 7 weeks ago

NeOnc Technologies: From Survival Mode To Expansion Mode

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Oct 9, 2025, 9:00 AM EDT - 7 weeks ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 29, 2025, 9:00 AM EDT - 2 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

Sep 10, 2025, 9:40 AM EDT - 2 months ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Sep 10, 2025, 9:00 AM EDT - 2 months ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 25, 2025, 9:00 AM EDT - 3 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Aug 11, 2025, 9:00 AM EDT - 3 months ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

Aug 7, 2025, 9:00 AM EDT - 4 months ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

Aug 4, 2025, 9:00 AM EDT - 4 months ago

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Jul 30, 2025, 9:00 AM EDT - 4 months ago

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

Jul 23, 2025, 10:53 AM EDT - 4 months ago

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

Jul 8, 2025, 9:00 AM EDT - 5 months ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

Jun 6, 2025, 9:00 AM EDT - 6 months ago

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

Apr 15, 2025, 8:05 AM EDT - 8 months ago

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

Apr 14, 2025, 8:05 AM EDT - 8 months ago

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

Apr 10, 2025, 8:05 AM EDT - 8 months ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Apr 8, 2025, 4:05 PM EDT - 8 months ago

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Mar 31, 2025, 8:05 AM EDT - 8 months ago

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Mar 27, 2025, 8:05 AM EDT - 8 months ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

Mar 25, 2025, 8:45 AM EDT - 8 months ago

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

Mar 25, 2025, 8:15 AM EDT - 8 months ago

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

Jan 4, 2025, 12:30 AM EST - 11 months ago

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

AERO CAPS CRGT FBGL FLOC INLF INR

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

Oct 7, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

Aug 5, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

Jul 16, 2024, 11:15 AM EDT - 1 year ago

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

Jun 26, 2024, 4:39 PM EDT - 1 year ago

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

May 15, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

May 9, 2024, 5:30 PM EDT - 1 year ago

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

Mar 30, 2024, 1:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

BOLD MMA MNDR NTCL ROTR UBXG WAY

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

Dec 25, 2023, 9:05 AM EST - 2 years ago

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

LGCB MAMO LZMH

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

Dec 20, 2023, 2:38 PM EST - 2 years ago

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

NeOnc_Technologies
NeOnc_Technologies Nov. 26 at 1:22 PM
$NTHI Amir Heshmatpour on recent completion of enrollment in pivotal NEO100 Phase 2a trial for IDH-1 mutant recurrent high-grade glioma and expectation of interim data readout in Q2 2026: “Having now completed full enrollment, we can comprehensively assess NEO100’s impact across a complete patient population. The strength of the data observed to date reinforces our confidence that our proprietary intranasal delivery platform — uniquely designed to bypass the blood-brain barrier represents a breakthrough approach for treating aggressive brain tumors. We believe these data will not only strengthen our clinical position but also strategically advance NeOnc toward becoming a global leader in CNS oncology innovation, with a first-mover advantage and a defensible moat protecting our extensive intellectual property portfolio.”
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 26 at 5:29 AM
$NTHI NeOnc Technologies Holdings Inc. (OTC:NTHI) delivered a major breakthrough in CNS oncology with NEO100 showing a 21 percent response rate versus less than 8 percent historically, 44 percent six-month PFS, and 33 percent eighteen-month survival in recurrent high-grade gliomas. As NTHI advances toward a May 2026 top-line readout and a $50 million Middle East partnership, investor interest is surging. https://biotechhealthx.com/biotech-news/neonc-technologies-nthi-stuns-wall-street-with-breakthrough-21-response-rate-in-brain-cancer-trial/
0 · Reply
topstockalerts
topstockalerts Nov. 25 at 8:03 PM
Top Gainers PT2 $BNED $WSHP $NTHI $QNTM $KZIA
0 · Reply
topstockalerts
topstockalerts Nov. 25 at 7:51 PM
$NTHI It wants to move higher..
0 · Reply
50shadesoftrades
50shadesoftrades Nov. 25 at 7:33 PM
$CETY $CSTE $PAVS $DKI $NTHI Intraday gainers https://go.trade-ideas.com/SH16c
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 25 at 8:22 AM
$NTHI NeOnc Technologies delivered a strong Q3 marked by strategic expansion in the Middle East, meaningful non-dilutive funding, enhanced market visibility, and strengthened leadership across both corporate and scientific fronts. Middle East Expansion: NuroMENA appointed His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signed an MSA with M42’s IROS, completed ADGM incorporation, and advanced a proposed $50M partnership with Quazar Investment. Non-Dilutive Funding: Awarded $2.5M in NIH STTR grants to advance NEO212 for gliomas and leukemia. Tech Expansion: Executed agreement to acquire advanced AI + 3D bioprinting IP. Media Visibility: Featured on Fox Business, Bloomberg TV, Yahoo Finance’s Trader Talk, a 12-part New to The Street campaign, and a live interview with Kenny Polcari. Index Inclusion: Added to the Russell Microcap® Index. IP Strength: Global patents protecting core CNS oncology assets. https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-holdings-reports-third-quarter-2025-results
0 · Reply
AlertsAndNews
AlertsAndNews Nov. 25 at 3:31 AM
$NTHI insider action here Neonc Technologies Holdings, Inc.: Amir F. Heshmatpour (Director, President, 10%+) Buys 30,000 Shares @ Avg Price $6.16 – Form 4
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 20 at 10:05 AM
$NTHI NeOnc Technologies Q3 2025 Financial Results & Operational Highlights NeOnc Technologies delivered a defining Q3 2025 Financial Results and Operational Highlights, advancing both clinical and strategic milestones: - G&A expenses: $903K vs. $244K in Q3 2024, reflecting expanded marketing, travel, and Middle East partnership-related costs. - R&D expenses: $715K vs. $957K in Q3 2024, supporting NEO100 trial site management, patient recruitment, NEO212 preparation, and initiation of NEO100-3. - Net loss: $8.6M ($0.45 per share) vs. $2.2M ($0.12 per share) in Q3 2024, primarily due to increased G&A and stock-based compensation. Amir Heshmatpour: “Q3 2025 positions NeOnc at the forefront of innovation in CNS oncology. We delivered encouraging Phase 2a NEO100 data, signaling a potential paradigm shift for recurrent high-grade gliomas. We also achieved FDA clearance for NEO212 Phase 2 trials, strengthening the depth and momentum of our pipeline.”
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 18 at 10:04 AM
$NTHI Last week was an incredible week for NeOnc. We announced 3 milestones that together underscore our momentum and position us for meaningful value creation in the CNS oncology space: Updated NEO100 clinical results: In 24 patients with recurrent IDH1‑mutant high-grade gliomas, NEO100 showed a 21% radiographic response rate, 44% progression-free survival at 6 months, and 33% of patients alive at 18+ months. No significant chronic toxicity was observed. Full enrollment of pivotal Phase 2a trial: Our trial for recurrent IDH1-mutant high-grade gliomas is now fully enrolled. Interim data is expected in Q2 2026. Q3 2025 results & operational updates: $50M strategic partnership via NuroMENA, $2.5M in STTR grants to advance NEO212, and listing in the Russell Microcap® Index. Net loss of $8.6M reflects strategic investment in pipeline growth. This is only the beginning for NeOnc. We aim to transform CNS oncology and bring new hope to patients.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 17 at 11:35 PM
$NTHI NeOnc Technologies: Exciting Upcoming Catalysts • We’re entering a pivotal period for value creation with three major near-term milestones: • Q4 2025: Completion of NEO212 Phase I final cohort dosing. • May 2026: Top-line data readout from NEO100-01 pivotal Phase 2a trial. Near-term: Closing and funding of the $50M Quazar Investment, supporting our CNS oncology pipeline and strategic growth. These catalysts mark critical steps in advancing our mission to deliver innovative therapies for patients with challenging CNS cancers. #CNSOncology #ClinicalTrials #Biotech #Investors #NEO100 #NEO212
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 16 at 1:33 PM
$NTHI “Completing enrollment for our Phase 2a trial marks a defining inflection point for NeOnc Technologies,” said Amir Heshmatpour, Executive Chairman, President & CEO. This milestone follows the Company’s recent announcement of positive results from a 24-patient cohort treated with NEO100. The findings were presented to the investment community during NeOnc’s November 12, 2025, investor conference call, which is available for replay at: https://www.webcaster5.com/Webcast/Page/3151/53234
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 14 at 9:32 PM
$NTHI Q3 reflects a development-stage company allocating resources to advance its two core CNS-oncology programs. The company reported no product revenue, as expected, and directed spending toward clinical operations, trial support, and the infrastructure required for upcoming milestones. Q3 expenses reflect continued investment in R&D and clinical infrastructure. Operating costs also include non-cash items tied to stock-based compensation and uplisting-related obligations. The company ended the quarter with ~$1.5M in cash and continued using its equity facilities to support operations—standard for a clinical-stage biotech preparing for multiple data points. Looking Ahead NeOnc enters Q4 focused on clinical execution, data generation, and resource management. The most relevant indicators remain the progress of NEO100 and NEO212 as the company advances toward its next set of data-driven inflection points.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 13 at 11:13 AM
$NTHI Amir F. Heshmatpour, Executive Chairman, President & CEO of NeOnc Technologies, stated: “With these data, we believe NeOnc stands at the threshold of a true game-changer for one of medicine’s greatest unmet needs—recurrent IDH1-mutant hi grade gliomas. For the first time, we’re witnessing evidence of meaningful radiographic responses and support for durable survival in patients who previously had few, if any, options. As we approach full enrollment of the NEO100 trial—and our full data readout six months post-enrollment—we believe this may represent a potential paradigm shift in the treatment of brain cancer. The data will speak for itself—and for the patients whose lives we are determined to transform.” Mr. Heshmatpour added: “We view this trial as a pivotal value inflection point for NeOnc and for the broader neuro-oncology field signaling a potential move beyond palliation toward measurable, durable disease control and a possible new standard of care in malignant gliomas.”
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 12 at 4:00 PM
$NTHI Incredible Milestone News: NeOnc Technologies Reports Updated Clinical Results Results of Clinical Trials Provide Evidence Supporting Significant Radiographic Response and Potential Long-Term Survival in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100 https://finance.yahoo.com/news/neonc-technologies-reports-updated-clinical-130000491.html
0 · Reply
jdlman
jdlman Nov. 11 at 10:10 PM
$NTHI nice day
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 11 at 11:00 AM
$NTHI In just 3 hours from now, NeOnc Technologies will host an investor conference call and webcast at 9:00 AM EST to present data updates from the ongoing NEO100-1 phase 1/2a clinical trial and compassionate use program. Watch the live webcast at the following link: https://www.webcaster5.com/Webcast/Page/3151/53234
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 10 at 10:12 AM
$NTHI NeOnc Technologies will host an investor conference call and webcast on Wednesday, November 12, 2025, at 9:00 AM EST, to present data updates from ongoing NEO100-1 phase 1/2a clinical trial and compassionate use program. Featured Participants: • Dr. Henry S. Friedman, MD – Deputy Director, Preston Robert Tisch Brain Tumor Center, Duke University; Independent Member, NTHI Scientific Advisory Board • Dr. Alexander Miller, MD – Chief Neuro-oncology, Brain Tumor Program, NYU Langone Health; Independent Member, NTHI Scientific Advisory Board • Amir Heshmatpour – Chief Executive Officer, Executive Chairman and President • Dr. Thomas C. Chen, MD, PhD – Chief Medical Officer and Chief Scientific Officer • Dr. Josh Neman, PhD – Chief Clinical Officer • Keith Garnett – Chief Financial Officer Conference Call Details: Date: Wednesday, November 12, 2025 Time: 6:00 a.m. PT / 9:00 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/3151/53234
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 9 at 9:36 AM
$NTHI “It has been the honor of a lifetime to found NeOnc and lead it to this pivotal stage, and I have the utmost confidence that Amir is the ideal leader to steer the company into its future,” said Dr. Thomas Chen, Founder, CMO and CSO of NeOnc. “His proven expertise in corporate strategy, capital formation, and global business development is precisely what NeOnc needs as we advance our lead candidates toward commercialization. This transition allows me to dedicate my full attention to what I am most passionate about: accelerating our clinical trials and driving the science that has the potential to transform outcomes for patients with brain cancer.”
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 6 at 9:50 AM
$NTHI NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Directors, ensuring his continued leadership over NeOnc's innovative scientific strategy and clinical development. https://www.globenewswire.com/news-release/2025/11/04/3180411/0/en/NeOnc-Technologies-Appoints-Amir-Heshmatpour-as-Chief-Executive-Officer-to-Drive-Next-Phase-of-Clinical-and-Corporate-Growth.html
0 · Reply
U_rappoport
U_rappoport Nov. 5 at 2:39 PM
$NTHI this level of transparency 🙌
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 5 at 12:52 PM
$NTHI At NeOnc Technologies, our world-class leadership team unites scientific innovation with strategic vision to transform brain and central nervous system therapeutics. Led by Executive Chairman Amir Heshmatpour and Founder & CEO Dr. Thomas Chen, alongside CFO Keithly A. Garnett and Chief Clinical Officer Dr. Josh Neman, our leaders bring deep expertise in science, medicine, and business. Guided by a distinguished Board and Scientific Advisory Board, including leading clinicians and researchers such as Dr. David Ashley, Dr. Henry Friedman, and Dr. Steven Giannotta, we are pioneering new standards of care for patients worldwide. Our mission is clear: advance groundbreaking therapies, deliver meaningful patient outcomes, and create lasting value for all stakeholders.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 4 at 1:31 PM
$NTHI October has been an exciting month for NeOnc Technologies, marked by three significant announcements: • NuroMENA Signs Master Services Agreement with M42’s IROS and Expands Board of Directors: Our subsidiary, NuroMENA, strengthened its strategic footprint through this agreement, positioning us for accelerated growth and innovation. • His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies’ Subsidiary: Strengthening UAE-US collaboration to advance breakthrough brain cancer treatment. • Appointment of Dr. David M. Ashley to Scientific Advisory Board: Dr. Ashley, Director of the Preston Robert Tisch Brain Tumor Center at Duke, joined our Scientific Advisory Board, bringing unparalleled expertise in neuro-oncology research and clinical practice. • Appointment of Dr. Alexandra M. Miller to Scientific Advisory Board: Dr. Miller joined our Scientific Advisory Board, further strengthening our leadership in cutting-edge brain tumor research.
0 · Reply